Mesothelioma can be difficult to distinguish from other cancers, particularly in the absence of a single specific and reliable marker².

• Lung cancers can vary substantially in appearance and differentiation from microscopic field to field.
• The diagnostic value of antibodies and immunohistochemical panels is still under debate.
• Pathological diagnosis often suffers from significant interobserver variability.

Significant shortcomings are associated with the methods currently used to diagnose mesothelioma^2,3. Pathologists and physicians need a better way to diagnose patients and develop treatment plans in a timely fashion.

miRview® meso is a cutting-edge, microRNA-based molecular diagnostic tool that provides physicians and pathologists with a clear, distinct diagnosis in patients with mesothelioma. It differentiates mesothelioma from other cancers of the lung and pleura with:

• Accuracy
• Speed
• Simple interpretation
• Quantitative analysis
• Objective results
• Cutting-edge molecular biology

1. Klebe S, Mahar A, Henderson DW, Roggli VL. Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review. Mod Pathol. 2008;21(9):1084-1094.
2. Marchevsky AM. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med. 2008;132(3):397-401.
3. Stang A, Pohlabeln H, Müller KM, Jahn I, Giersiepen K, Jöckel KH. Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer. 2006;52(1):29-36.